What is HC Wainwright’s Forecast for ALNY FY2028 Earnings?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Analysts at HC Wainwright lifted their FY2028 earnings estimates for shares of Alnylam Pharmaceuticals in a research report issued on Monday, July 13th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earnings of $12.46 per share for the year, up from their prior forecast of $12.15. HC Wainwright has a “Buy” rating and a $485.00 price objective on the stock. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is $7.29 per share. HC Wainwright also issued estimates for Alnylam Pharmaceuticals’ FY2029 earnings at $16.28 EPS and FY2030 earnings at $20.67 EPS.

Several other brokerages have also recently commented on ALNY. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 7th. Truist Financial lowered their target price on shares of Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a research note on Monday. Citigroup assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Tuesday, May 19th. They set a “buy” rating and a $380.00 price target on the stock. Chardan Capital reissued a “buy” rating and issued a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Finally, Wells Fargo & Company boosted their price objective on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a research note on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $455.31.

Alnylam Pharmaceuticals Trading Down 2.4%

Shares of ALNY stock opened at $281.26 on Wednesday. Alnylam Pharmaceuticals has a 1-year low of $273.11 and a 1-year high of $495.55. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The stock has a market cap of $37.55 billion, a price-to-earnings ratio of 76.85 and a beta of 0.27. The stock has a 50-day moving average of $295.45 and a 200-day moving average of $323.24.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company’s revenue was up 96.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.44) EPS.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ALNY. iA Global Asset Management Inc. boosted its position in Alnylam Pharmaceuticals by 979.5% during the fourth quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock worth $7,070,000 after purchasing an additional 16,133 shares during the period. Perpetual Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $2,004,000. Linden Advisors LP bought a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $6,550,000. Hussman Strategic Advisors Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $2,505,000. Finally, Groupama Asset Managment lifted its position in shares of Alnylam Pharmaceuticals by 160.4% during the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after acquiring an additional 2,483,697 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares in the company, valued at approximately $473,302.76. The trade was a 70.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.